Home / Recalls / QuVa Pharma, Inc. / D-0548-2020

D-0548-2020 Class II Terminated

Recalled by QuVa Pharma, Inc. — Sugar Land, TX

Recall Details

Product Type
Drugs
Report Date
December 11, 2019
Initiation Date
November 12, 2019
Termination Date
June 5, 2020
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity

Product Description

fentaNYL 200 mcg/100 mL (2 mcg/mL) ROPivacaine HCl 0.2% 200 mg/100 mL (2 mg/mL) in 0.9% Sodium Chloride 100 mL CADD, Rx, QuVA Pharma 1075 West Park One Drive, Suite 100 Sugar Land, TX 77478NDC 70092-1259-75

Reason for Recall

Presence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass particules

Distribution Pattern

Nationwide.

Code Information

Lots: 10029829 Exp. 11/18/2019, 10029883 Exp. 11/19/2019, 10029829 Exp. 11/18/2019, 10029883 Exp. 11/19/2019, 10030056 Exp. 11/24/2019, 10029883 Exp. 11/19/2019, 10030867 Exp. 11/27/2019, 10030056 Exp. 11/24/2019, 10031005 Exp. 12/4/2019, 10030950 Exp. 12/3/2019, 10031005 Exp. 12/4/2019, 10031103 Exp. 12/6/2019, 10031006 Exp. 12/4/2019, 10031142 Exp. 12/8/2019, 10031274 Exp. 12/10/2019, 10031710 Exp. 12/12/2019, 10031628 Exp. 12/19/2019, 10031777 Exp. 12/22/2019, 10031683 Exp. 12/22/2019, 10032050 Exp. 12/29/2019, 10032051 Exp. 12/29/2019, 10032435 Exp. 1/2/2020, 10032468 Exp. 1/2/2020, 10032545 Exp. 1/5/2020, 10032676 Exp. 1/8/2020, 10032677 Exp. 1/8/2020, 10032595 Exp. 1/6/2020, 10032545 Exp. 1/5/2020, 10032596 Exp. 1/6/2020

Other recalls by QuVa Pharma, Inc.

  • D-0113-2026 Class II — R.E.C.K. (Ropivacaine HCl, EPINEPHrine, CloNIDine HCl, and Ketorolac Tromethamin (October 10, 2025)
  • D-0297-2025 Class II — fentaNYL Citrate PF 200 mcg/100 mL (2 mcg/ml) /0.2% ROPivacaine HCl 200 mg/100 m (March 6, 2025)
  • D-0295-2025 Class II — fentaNYL Citrate PF 200 mcg/100 mL (2 mcg/ml) /0.1% Bupivacaine HCl 100 mg/100 m (March 6, 2025)
  • D-0296-2025 Class II — fentaNYL Citrate PF 200 mcg/100 mL (2 mcg/ml) /0.125% Bupivacaine HCl 125 mg/100 (March 6, 2025)
  • D-1544-2022 Class III — oxyTOCIN 30 Units/500 mL (0.06 Units/mL) added to 0.9% Sodium Chloride, Injectio (September 20, 2022)
  • D-1302-2020 Class II — oxyTOCIN 30 Units/500 mL (0.06 Units/mL) added to 0.9% Sodium Chloride Injection (May 28, 2020)
  • D-1335-2020 Class III — R.E.C.K. (Ropivacaine, Epinephrine, Clonidine, Ketorolac) in Sodium Chloride sol (April 23, 2020)
  • D-0554-2020 Class II — fentaNYL 400 mcg/200 mL (2 mcg/mL) ROPivacaine HCl 0.2% 400 mg/200 mL (2 mg/mL) (November 12, 2019)
  • D-0547-2020 Class II — fentaNYL 500 mcg/250 mL (2 mcg/mL) 0.125% BUPivacaine HCl 312.5 mg/250 mL (1.25 (November 12, 2019)
  • D-0555-2020 Class II — fentaNYL 1000 mcg/100 mL (10 mcg/mL) in 0.9% Sodium Chloride Preservative Free, (November 12, 2019)